N-{3-[6-ethyl-3-(2-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-ylmethyl)-3-aza-bicyclo[3.1.0]hex-6-yl]-phenyl}-methanesulfonamide | 845621-30-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-{3-[6-ethyl-3-(2-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-ylmethyl)-3-aza-bicyclo[3.1.0]hex-6-yl]-phenyl}-methanesulfonamide
• 英文别名: (+)-exo-N-{3-[6-Ethyl-3-(2-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-ylmethyl)-3-aza-bicyclo[3.1.0]hex-6-yl]-phenyl}-methanesulfonamide；N-[3-[6-ethyl-3-[(2-hydroxy-3,4-dihydro-1H-naphthalen-2-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]phenyl]methanesulfonamide
• CAS: 845621-30-9
• 化学式: C₂₅H₃₂N₂O₃S
• 分子量: 440.607
• InChiKey: PCSVBTAEAGRKJN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  78
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• 3-azabicyclo[3.1.0]hexane derivatives
  申请人：Pfizer Inc.

  公开号：US20030087898A1

  公开（公告）日：2003-05-08

  The subject invention provides a compound of the formula 1, 1 wherein X, Q, n, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are as defined. Compounds of formula I have activity as opioid receptor antagonists. The subject invention furthermore provides for pharmaceutical compositions and therapeutic methods comprising compounds of formula I.

  本主题发明提供了一个化合物的公式1,1，其中X、Q、n、R1、R2、R3、R4、R5、R6、R7、R8、R9和R10如所定义。公式I的化合物具有作为阿片受体拮抗剂的活性。此外，该主题发明还提供了包含公式I化合物的药物组合物和治疗方法。
• Pharmaceutical composition for the prevention and treatment of addiction in a mammal
  申请人：Coe Wadsworth Jotham

  公开号：US20050043327A1

  公开（公告）日：2005-02-24

  Pharmaceutical compositions are disclosed for the treatment of alcohol or cocaine dependence or addiction, tobacco dependence or addiction, reduction of alcohol withdrawal symptoms or aiding in the cessation or lessening of alcohol use or substance abuse or other behavioral dependencies including gambling. The pharmaceutical compositions are comprised of a therapeutically effective combination of an opioid receptor antagonist and a CB-1 receptor antagonist and a pharmaceutically acceptable carrier. The method of using these compounds is also disclosed.

  本发明公开了用于治疗酒精或可卡因依赖或成瘾、烟草依赖或成瘾、减轻酒精戒断症状或帮助停止或减轻酒精使用或药物滥用或包括赌博在内的其他行为依赖的药物组合物。药物组合物由阿片受体拮抗剂和 CB-1 受体拮抗剂的治疗有效组合以及药学上可接受的载体组成。还公开了使用这些化合物的方法。
• Process for preparing an azabicyclo[3.1.0] hexane compound
  申请人：Tickner L. Derek

  公开号：US20050075387A1

  公开（公告）日：2005-04-07

  A process for preparing azabicyclo[3.1.0]hexane compounds having reduced process-related impurities, e.g. 3-azabicyclo[3.1.0]hexane derivatives having reduced levels of etheric impurities, e.g. THF, is disclosed.

  本发明公开了一种制备氮杂双环[3.1.0]己烷化合物的工艺，该工艺可减少与工艺相关的杂质，例如可减少乙醚杂质（如四氢呋喃）含量的 3-氮杂双环[3.1.0]己烷衍生物。
• 3-Azabicyclo[3.1.0]hexane derivatives
  申请人：McHardy F. Stanton

  公开号：US20050171178A1

  公开（公告）日：2005-08-04

  The subject invention provides a compound of the formula I, wherein X, Q, n, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are as defined. Compounds of formula I have activity as opioid receptor antagonists. The subject invention furthermore provides for pharmaceutical compositions and therapeutic methods comprising compounds of formula I.

  本发明提供了一种式 I 的化合物、 其中 X、Q、n、R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 和 R 10 的定义相同。式 I 的化合物具有阿片受体拮抗剂的活性。本发明还提供了包含式 I 化合物的药物组合物和治疗方法。
• 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS
  申请人：Pfizer Products Inc.

  公开号：EP1440059B1

  公开（公告）日：2008-04-16